NASDAQ: SYRSSyros Pharmaceuticals Inc Stock Ownership - Who owns Syros Pharmaceuticals?
Insider buying vs selling
Have Syros Pharmaceuticals Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| David Roth | Chief Medical Officer | 2024-04-03 | 10,451 | $4.95 | $51.73kSell |
| David Roth | Chief Medical Officer | 2024-04-02 | 150 | $4.98 | $747.00Sell |
| Conley Chee | President CEO | 2024-04-01 | 3,500 | $5.12 | $17.92kSell |
| Nancy A. Simonian | Director | 2024-04-01 | 14,052 | $5.12 | $71.95kSell |
| Jason Haas | Chief Financial Officer | 2024-04-01 | 4,732 | $5.12 | $24.23kSell |
| David Roth | Chief Medical Officer | 2024-04-01 | 4,732 | $5.12 | $24.23kSell |
| Kristin Stephens | Chief Development Officer | 2024-04-01 | 4,218 | $5.12 | $21.60kSell |
| Gerald E. Quirk | Chief Legal Compliance Offic | 2024-03-28 | 7,046 | $5.59 | $39.39kSell |
| Srinivas Akkaraju | Director | 2023-12-21 | 904,977 | $4.42 | $4.00MBuy |
| David Roth | Chief Medical Officer | 2023-12-12 | 6,287 | $4.95 | $31.12kSell |
SYRS insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when SYRS insiders and whales buy or sell their stock.
SYRS Shareholders
What type of owners hold Syros Pharmaceuticals Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Robert Nelsen | 18.34% | 4,850,470 | $24.59M | Insider |
| Arch Venture Fund Vii LP | 16.04% | 4,242,051 | $21.51M | Insider |
| Srinivas Akkaraju | 14.10% | 3,730,481 | $18.91M | Insider |
| Bain Capital Life Sciences Investors LLC | 10.39% | 2,749,808 | $13.94M | Institution |
| Artal Group Sa | 9.47% | 2,505,013 | $12.70M | Institution |
| Flagship Ventures Fund Iv LP | 9.08% | 2,403,190 | $12.18M | Insider |
| James E. Flynn | 7.92% | 2,095,220 | $10.62M | Insider |
| Adage Capital Partners GP LLC | 7.83% | 2,071,914 | $10.50M | Institution |
| Samsara Biocapital LLC | 6.75% | 1,786,427 | $9.06M | Institution |
| Avidity Partners Management LP | 6.33% | 1,673,538 | $8.48M | Institution |
SYRS vs Biotech Stocks
Syros Pharmaceuticals Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.